نتائج البحث - "Kopyltsov E."

11

دورية أكاديمية

Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma

المساهمون: Motzer, R., Alekseev, B., Rha, S. -Y., Porta, C., Eto, M., Powles, T., Grunwald, V., Hutson, T. E., Kopyltsov, E., Mendez-Vidal, M. J., Kozlov, V., Alyasova, A., Hong, S. -H., Kapoor, A., Gordoa, T. A., Merchan, J. R., Winquist, E., Maroto, P., Goh, J. C., Kim, M., Gurney, H., Patel, V., Peer, A., Procopio, G., Takagi, T., Melichar, B., Rolland, F., de Giorgi, U., Wong, S., Bedke, J., Schmidinger, M., Dutcus, C. E., Smith, A. D., Dutta, L., Mody, K., Perini, R. F., Xing, D., Choueiri, T. K., Boccardo, F.

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33616314; info:eu-repo/semantics/altIdentifier/wos/WOS:000637799800007; volume:384; firstpage:1289; lastpage:1300; numberofpages:12; journal:NEW ENGLAND JOURNAL OF MEDICINE; http://hdl.handle.net/11567/1046356Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85103105017

الإتاحة: https://doi.org/10.1056/NEJMoa2035716Test
http://hdl.handle.net/11567/1046356Test

View record in BASE

12

دورية أكاديمية

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

المؤلفون: Powles T., van der Heijden M. S., Castellano D., Galsky M. D., Loriot Y., Petrylak D. P., Ogawa O., Park S. H., Lee J. -L., De Giorgi U., Bogemann M., Bamias A., Eigl B. J., Gurney H., Mukherjee S. D., Fradet Y., Skoneczna I., Tsiatas M., Novikov A., Suarez C., Fay A. P., Duran I., Necchi A., Wildsmith S., He P., Angra N., Gupta A. K., Levin W., Bellmunt J., Lee J. L., Westgeest H., Flechon A., Ou Y. -C., Park I., Matveev V., Perez-Valderrama B., Cheng S., Frank S., Anido U., Hamzaj A., Retz M., Sridhar S., Scagliotti G. V., Voortman J., Alekseev B., Alyasova A., Komyakov B., Dumez H., Pavic M., Kimura G., Mizokami A., Osanto S., Arranz J. A., Piersma D., Shin S. J., Karyakin O., Delgado I., Gonzalez J. L., Pang S. -T., Tran A., Lipatov O., Su W. -P., Flaig T., Alva A., Park Kyong H., Kopyltsov E., Almagro E., Domenech M., Chang Y. -H., Sautois B., Ravaux A., Aravantinos G., Georgoulias V., Mulder S., Kim Y. J., Kater F., Chevreau C., Tagawa S., Zalewski P., Joly F., Hatiboglu G., Gianni L., Morelli F., Tambaro R., Hashimoto Y., Nosov A., Font A., Rodriguez-Vida A. M., Jones R., Vasudev N., Srinivas S., Zhang J., Gil T., Finch D., Grimm M. -O., Su Y. -L., Chowdhury S., Hocking C., Plas E., North S., Jensen N. V., Theodore C., Imkamp F., Peer A., Kobayashi T., Sakai H., Sassa N., Yoshimura K., Aarts M., Ferreira Castro A., Topuzov M., Rodriguez J. F., Vazquez F. J., Tsai Y. -C., Crabb S., Hussain S., Bendell J., Gross-Goupil M., Gwenaelle G., Berger R., Statsenko G., Evans L., Drakaki A., Somer B., Davis I., Lynam J., Borges G., Dettino A., Martins G., Zucca L. E., Agerbaek M., Kalofonos H., Rosenbaum E., Enokida H., Kikukawa H., Nishimura K., Tamada S., Uemura M., Lopez Y., Gietema J., Slojewski M., Fernandes I., Smolin A., Mazhar D., Kalebasty A. R., Carthon B., Loidl W., Franke F., Girotto G., Alimohamed N., Macfarlane R., Pappot H., Niegisch G., Mavroudis D., Sella A., Porta C., Ebara S., Nakamura M., Obara W., Okuno N., Shinohara N., Sugimoto M., Suzuki A., Tokuda N., Uemura H., Yamaguchi A., Ramirez F., Rozanowski P., Wiechno P., Keam B., Kislov N., Plaksin D., Cicin I., Kumar S., Rosales J., Vaishampayan U., Culine S., Papandreou C., Nara T., Erman M., Kreiger L., Janoski J., Rosa D., Siqueira M., Canil C., Sengelov L., Tourani J. -M., Arai G., Hashine K., Kawakita M., Nakaigawa N., Nomi H., Shiina H., Suzuki H., Yonese J., Kuri R., Macedo E., Rivera S., Villalobos Prieto A., Polakiewicz-Gilowska A., Zaucha R., Lopes F., Ponomarev R., Pomerantz M., Shariat S., Luk C., Lesniewski-Kmak K.

المساهمون: Powles, T., van der Heijden, M. S., Castellano, D., Galsky, M. D., Loriot, Y., Petrylak, D. P., Ogawa, O., Park, S. H., Lee, J. -L., De Giorgi, U., Bogemann, M., Bamias, A., Eigl, B. J., Gurney, H., Mukherjee, S. D., Fradet, Y., Skoneczna, I., Tsiatas, M., Novikov, A., Suarez, C., Fay, A. P., Duran, I., Necchi, A., Wildsmith, S., He, P., Angra, N., Gupta, A. K., Levin, W., Bellmunt, J., Lee, J. L., Westgeest, H., Flechon, A., Ou, Y. -C., Park, I., Matveev, V., Perez-Valderrama, B., Cheng, S., Frank, S., Anido, U., Hamzaj, A., Retz, M., Sridhar, S., Scagliotti, G. V., Voortman, J., Alekseev, B., Alyasova, A., Komyakov, B., Dumez, H., Pavic, M., Kimura, G., Mizokami, A., Osanto, S., Arranz, J. A., Piersma, D., Shin, S. J., Karyakin, O., Delgado, I., Gonzalez, J. L., Pang, S. -T., Tran, A., Lipatov, O., Su, W. -P., Flaig, T., Alva, A., Park Kyong, H., Kopyltsov, E., Almagro, E., Domenech, M., Chang, Y. -H., Sautois, B., Ravaux, A., Aravantinos, G., Georgoulias, V., Mulder, S., Kim, Y. J., Kater, F., Chevreau, C., Tagawa, S., Zalewski, P., Joly, F., Hatiboglu, G., Gianni, L., Morelli, F., Tambaro, R., Hashimoto, Y., Nosov, A., Font, A., Rodriguez-Vida, A. M., Jones, R., Vasudev, N., Srinivas, S., Zhang, J., Gil, T., Finch, D., Grimm, M. -O., Su, Y. -L.

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000599899200041; volume:21; issue:12; firstpage:1574; lastpage:1588; numberofpages:15; journal:THE LANCET ONCOLOGY; http://hdl.handle.net/20.500.11768/110034Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85091519786

الإتاحة: https://doi.org/20.500.11768/110034Test
https://doi.org/10.1016/S1470-2045Test(20)30541-6
https://hdl.handle.net/20.500.11768/110034Test

View record in BASE

13

دورية أكاديمية

Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma

المصدر: Choueiri , T K , Tomczak , P , Park , S H , Venugopal , B , Ferguson , T , Chang , Y H , Hajek , J , Symeonides , S N , Lee , J L , Sarwar , N , Thiery-Vuillemin , A , Gross-Goupil , M , Mahave , M , Haas , N B , Sawrycki , P , Gurney , H , Chevreau , C , Melichar , B , Kopyltsov , E , Alva , A , Burke , J M , Doshi , G , Topart , D , ....

الإتاحة: https://doi.org/10.1056/nejmoa2106391Test
https://researchers.mq.edu.au/en/publications/239c4bed-f6b8-4786-9cab-d4e55039d85aTest
http://www.scopus.com/inward/record.url?scp=85113283089&partnerID=8YFLogxKTest

View record in BASE

14

دورية أكاديمية

Clinical benefit and safety profile of darolutamide in patients who crossed over to darolutamide from placebo during the open-label period of the phase 3 ARAMIS study

المؤلفون: Feyerabend, S., Shore, N., Smith, M., Kopyltsov, E., Antonyan, I., Damber, J., Gasparro, D., Yildirim, A., Hellstrom, M., Vjaters, E., Ortiz, J., Srinivasan, S., Sarapohja, T., Fizazi, K.

المصدر: European Urology ; volume 79, page S1742-S1743 ; ISSN 0302-2838

مصطلحات موضوعية: Urology

الإتاحة: https://doi.org/10.1016/s0302-2838Test(21)01598-0
https://api.elsevier.com/content/article/PII:S0302283821015980?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0302283821015980?httpAccept=text/plainTest

View record in BASE

15

Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC) : depth of response and efficacy for selected subgroups in the lenvatinib (L) plus pembrolizumab (P) and sunitinib (S) treatment arms

المؤلفون: Grünwald, Viktor, Powles, T., Kopyltsov, E., Kozlov, V., Alonso Gordoa, T., Eto, M., Hutson, T., Motzer, R., Winquist, E., Maroto, P., Keam, B., Procopio, G., Wong, S., Melichar, B., Rolland, F., Oya, M., Rodriguez-Lopez, K., Saito, K., Smith, A., Porta, C.

مصطلحات موضوعية: Medizin

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=unidue___bib::c61e69a2aedfb0278cd96bb20c951dfeTest

16

Phase III CLEAR trial in advanced renal cell carcinoma (aRCC) : Outcomes in subgroups and toxicity update

المؤلفون: Choueiri, T.K., Eto, M., Kopyltsov, E., Rha, S.Y., Porta, C.G., Motzer, R., Grünwald, V., Hutson, T.E., Méndez-Vidal, M.J., Hong, S-H., Winquist, E., Goh, J.C.H., Maroto, P., Buchler, T., Takagi, T., Rodriguez-Lopez, K., Xing, D., Smith, A.D., Powles, T.

مصطلحات موضوعية: Medizin

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=unidue___bib::93985a79858421c972af41cc79af8524Test

17

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

المؤلفون: Motzer, R, Alekseev, B, Rha, SY, Porta, C, Eto, M, Powles, T, Grunwald, V, Hutson, TE, Kopyltsov, E, Mendez-Vidal, MJ, Kozlov, V, Alyasova, A, Hong, SH, Kapoor, A, Gordoa, TA, Merchan, JR, Winquist, E, Maroto, P, Goh, JC, Kim, M, Gurney, H, Patel, V, Peer, A, Procopio, G, Takagi, T, Melichar, B, Rolland, F, De Giorgi, U, Wong, S, Bedke, J, Schmidinger, M, Dutcus, CE, Smith, AD, Dutta, L, Mody, K, Perini, RF, Xing, DY, Choueiri, TK, CLEAR Trial Investigators

المصدر: NEW ENGLAND JOURNAL OF MEDICINE
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

مصطلحات موضوعية: Oncology, Male, Programmed Cell Death 1 Receptor, Medizin, Pembrolizumab, 030204 cardiovascular system & hematology, urologic and male genital diseases, chemistry.chemical_compound, 0302 clinical medicine, Renal cell carcinoma, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Sunitinib, Medicine, 030212 general & internal medicine, Humanized, Aged, 80 and over, General Medicine, Middle Aged, female genital diseases and pregnancy complications, Kidney Neoplasms, Progression-Free Survival, Quinolines, Female, Lenvatinib, medicine.drug, Adult, medicine.medical_specialty, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, Antibodies, 03 medical and health sciences, Internal medicine, Carcinoma, Humans, Progression-free survival, Everolimus, Carcinoma, Renal Cell, Protein Kinase Inhibitors, Aged, business.industry, Phenylurea Compounds, Renal Cell, medicine.disease, Survival Analysis, chemistry, business